Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021051 (
immunodeficiency
)
71,517
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Contraceptive research and development is currently addressing the preservation of female fertility through birth control, the promotion of birth control as an essential component of a healthy life-style, and prevention of the spread of sexually transmitted diseases. The combined oral contraceptive (OC) remains the most popular birth control method, and the introduction of new progestogens has lowered the incidence of cycle control problems and improved metabolic data. As protection against human
immunodeficiency
virus (HIV) transmission becomes a central concern among contraceptive users, the condom has increased in popularity. Recent innovations in the field of barrier methods include the female condom and cervical cap; plastic is being tested as a component of male condoms. Advances in IUD technology include Cu-safe 300 (a slim device with an anti-expulsion design), the flexigard (a frameless device associated with reduced pain and bleeding), and levonorgestrel-releasing devices. Among new contraceptive delivery systems are the vaginal ring,
Norplant
, and monthly combined injectables. Bioself 110, an electronic fertility indicator, refines the practice of natural family planning. For postpartum contraception, researchers are working on a delivery system for natural progesterone, and lactational amenorrhea has gained recognition as an effective method of pregnancy prevention.
...
PMID:New thinking in contraception. 184 13
A survey of medical and counseling staff at 13 family planning clinics in Texas suggested that contraceptive method selection, particularly with regard to
Norplant
, is closely linked to health care professionals; opinions about the various methods. Since all 13 clinics were operated by Planned Parenthood, the protocol for counseling was uniform. 65.2% of the 90 clinicians who completed questionnaires indicated they always or usually discussed
Norplant
with family planning patients. 7 facilities dispensed
Norplant
to less than 6% of their patients; the remaining 6 had distribution rates of at least 10.5%. Providers who had received in-service training on
Norplant
were significantly more likely than their informally educated counterparts to prescribe
Norplant
as were those who were aware the method had no permanent effect on future fertility. 29% of clinical staff at high distribution sites claimed they would recommend implants over sterilization compared to 8.3% of those at low distribution sites. An analysis of responses to opinion questions about
Norplant
indicated that there was a significant association (p 0.01) between the number of clients who received
Norplant
and staff members' agreement with the following items: a woman can use
Norplant
regardless of how many children she has, the high cost of the implants is worthwhile, the method is good for child spacing, the implants are a suitable method for women with human
immunodeficiency
virus (HIV) infection, and women under 18 years of age are appropriate candidates for its use. Overall, 35% of respondents believed
Norplant
posed a greater potential danger than the pill, 37% felt the implants were more dangerous than tubal ligation surgery, and 16% rated
Norplant
as more risky than the IUD; there was no association between perceptions of relative danger and patterns of distribution, however. Concerns about
Norplant
focused on the lack of screening criteria, its failure to protect against HIV, and a need for more research. The service provided to family planning clients would be improved with enhanced in-service training. The identification of women for whom
Norplant
is most suitable, and practitioner awareness of the extent to which personal opinions influence counseling approach.
...
PMID:The attitudes of clinic staff as factors in women's selection of Norplant implants for their contraception. 794 12
Although Thailand's National Family Planning Program introduced
Norplant
contraceptive implants in 1986, few women infected with human
immunodeficiency
virus (HIV) select this method, and its efficacy, clinical effects, and side effects in this population have not been investigated. To address these issues, a prospective cohort study was conducted during 1993-96 of 41 asymptomatic HIV-infected women who presented to the Family Planning Clinic at Ramathibodi Hospital in Bangkok, Thailand, and voluntarily accepted
Norplant
implants. All implants were inserted within 4 weeks after delivery or abortion. 63.4% of acceptors had not used any contraceptive method prior to pregnancy. At 6 and 12 months after insertion, 26% and 23%, respectively, reported irregular menstrual periods and 24.4% and 36.6%, respectively, reported amenorrhea. Side effects, reported by 3-10% of women, included headache, acne/chloasma, anorexia, and nausea. There were no significant changes in body weight, blood pressure, and hemoglobin between insertion and the 12-month follow-up. No pregnancies occurred during the study period. These findings suggest that
Norplant
implants are an effective, appropriate contraceptive method for HIV-infected women who want to avoid pregnancy but are not interested in sterilization.
...
PMID:Use of Norplant implants in asymptomatic HIV-1 infected women. 917 51
After a recent study showing that monkeys given progesterone are more likely to acquire simian
immunodeficiency
virus (SIV), women's reproductive health experts are advising clinicians to stress the importance of condom use and calm worried women by pointing out that other studies are needed to understand the relationship between hormones and HIV risk. Researchers have learned that progestin causes a thinning of the vaginal wall--possibly an explanation for the increase in SIV infection in the monkey study. Because Depo-Provera and
Norplant
are long-acting progestin-based contraceptives, women using them to prevent pregnancy may be especially alarmed by reports of the monkey study. Women should be advised that using these contraceptives do protect them from pregnancy; women should assess the risk of contracting HIV or other sexually transmitted diseases; and women should modify their behavior to lower their risk.
...
PMID:Advice for women seeking progesterone counseling. 1136 50
The recent finding that rhesus monkeys given progesterone were more likely to become infected after vaginal exposure to simian
immunodeficiency
virus than their nontreated counterparts has raised concerns about the effect of progestin-containing contraceptives on HIV risk. More research is needed to determine whether this finding extends to the progestins used in oral contraceptives,
Norplant
, injectables, and the levonorgestrel-containing IUD. Family Health International, in response to the animal study, reiterated its stance of support of dual contraceptive use: hormonal methods to prevent pregnancy and latex condoms to prevent sexually transmitted diseases.
...
PMID:Does progesterone increase HIV risk? Contraceptive update. 1229 87
Three women's groups registered their concerns and recommendations about the use of
Norplant
in Canada, where it was approved for use in November, 1993. The National Action Committee on the Status of Women had the following reservations: 1)
Norplant
requires trained personnel for its insertion and removal (both minor surgical procedures), which makes it controlled by the provider; 2) there is a potential for misuse without adequate informed consent, especially among welfare recipients, disabled women, or those whose first language is not English or French (women in the United States have been given financial incentives or had
Norplant
made a probation requirement); and 3) discontinuation rates have equalled 50% in clinical trials because of side effects that are often perceived differently because of culture. The Toronto Women's Health Network is concerned that
Norplant
use among teens, welfare recipients, and women of color will lead to higher rates of sexually transmitted disease (STD) and human
immunodeficiency
virus (HIV). The Women's Health Clinic has the following recommendations: 1) a clear policy with guidelines on informed consent, 2) an accredited certification program for health professionals that includes training and supervision of insertion, removal, and counseling techniques, and a process for client follow-up; 3) a policy limiting availability to centers with accredited staff and adequate infrastructure; 4) the development of a program that follows mobile patients, perhaps, via prescriptions; 5) the promotion of
Norplant
in professional literature only; 6) comprehensive and understandable patient education materials for women of diverse backgrounds; 7) ongoing qualitative and epidemiological studies designed with input from consumers and experts; and 8) reform of the drug approval process ensuring mechanisms for openness, consumer input and public discussion.
...
PMID:Norplant entered Canada through the back door. 1231 19